Schizophrenia (February)

Date of Issue: 02/01/2022 | Volume: 20 | Number: 2

Issue Links:Learning Objectives | Editorial Information

Brian Miller discusses tailoring treatments and improving the therapeutic alliance in patients with schizophrenia. A comprehensive look at gabapentin in psychiatry. Repurposing MDMA for drug-assisted psychotherapy in PTSD. A report of one of the studies of lumateperone that contributed to FDA approval for bipolar depression. Pilot studies suggest bupropion and naltrexone may be a contender in methamphetamine use disorder. A look at how Lybalvi stacks up against generic alternatives for weight gain on olanzapine.

In This Issue

Expert Q&A

Raising the Bar in Schizophrenia Treatment

Topics: Clozapine | Negative Symptoms | Psychosis | Schizophrenia | Second Generation Antipsychotics (SGAs)

Dr. Miller discusses new options for negative symptoms, how to improve the therapeutic alliance, and what to do when clozapine doesn’t work in schizophrenia.

Read More
Clinical Update

An Off-Label Guide to Gabapentin

Topics: Alcohol use disorder | Anxiety | Anxiety Disorder | Cannabis | Free Articles | gabapentin | Pregabalin

Off-label gabapentin (Neurontin) got a bad rep when it missed the mark in bipolar disorder, but there may be something worth salvaging in this drug. Here, we weigh its pros and cons for anxiety, substance use disorders, sleep, pain, and hot flashes, and compare it to its underutilized cousin, pregabalin (Lyrica).

Read More
Research Update

MDMA-Assisted Therapy for Severe PTSD

Topics: Drug-assisted psychotherapy | MDMA | Novel drug | Psychedelics | PTSD

MDMA is being repurposed as part of drug-assisted psychotherapy for PTSD, and this trial will help determine whether it gains FDA approval for that use.

Read More
Research Update

Lumateperone in Bipolar Depression

Topics: Bipolar Depression | Bipolar Disorder | Bipolar II | Lumateperone | Second Generation Antipsychotics (SGAs)

In December 2021, the FDA approved lumateperone (Caplyta) for bipolar I and II depression, and here we report on one of the trials that led to that approval.

Read More
Research Update

A Novel Treatment for Methamphetamine Use Disorder

Topics: Bipolar Depression | Bipolar Disorder | Bipolar II | Lumateperone | Second Generation Antipsychotics (SGAs)

With so few pharmacologic options for methamphetamine use disorder, a large trial from The New England Journal of Medicine suggest bupropion and naltrexone are worth exploring.

Read More
In Brief

Lybalvi: The Diet Olanzapine

Topics: Antipsychotics | Metabolic syndrome | Metformin | News of Note | Novel drug | Obesity | olanzapine | Side Effects | Waist circumference | Weight gain | Weight Loss Medications

Lybalvi hopes to lower the risk of weight gain on olanzapine by combining it with an opioid blocker (samidorphan). But how does it compare to generic options like metformin and naltrexone?

Read More
CME Post-Test

CME Post-Test - Schizophrenia, TCPR, February 2022

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.

Read More